Do analysts prefer PRCT or STVN?

PROCEPT BioRobotics presently has a consensus target price of $41.45, suggesting a potential upside of 48.96%. Given PROCEPT BioRobotics' higher probable upside, equities analysts plainly believe PROCEPT BioRobotics is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PROCEPT BioRobotics 2 Sell rating(s) 4 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.43 Stevanato Group 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media refer more to PRCT or STVN?

In the previous week, Stevanato Group had 2 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 5 mentions for Stevanato Group and 3 mentions for PROCEPT BioRobotics. Stevanato Group's average media sentiment score of 0.67 beat PROCEPT BioRobotics' score of 0.00 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BLCO or PRCT?

In the previous week, Bausch + Lomb had 2 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 5 mentions for Bausch + Lomb and 3 mentions for PROCEPT BioRobotics. Bausch + Lomb's average media sentiment score of 0.72 beat PROCEPT BioRobotics' score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PROCEPT BioRobotics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PRCT or LQDA?

In the previous week, Liquidia had 3 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 6 mentions for Liquidia and 3 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 0.00 beat Liquidia's score of -0.15 indicating that PROCEPT BioRobotics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PROCEPT BioRobotics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Liquidia 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LIVN or PRCT?

In the previous week, LivaNova and LivaNova both had 3 articles in the media. LivaNova's average media sentiment score of 0.09 beat PROCEPT BioRobotics' score of 0.00 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PROCEPT BioRobotics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PROCEPT BioRobotics (PRCT) Competitors

$27.83 +0.83 (+3.07%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$27.76 -0.07 (-0.25%)

As of 06/5/2026 07:59 PM Eastern

Compare

PRCT vs. STVN, BLCO, LQDA, LIVN, and NVST

Should you buy PROCEPT BioRobotics stock or one of its competitors? MarketBeat compares PROCEPT BioRobotics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PROCEPT BioRobotics include Stevanato Group (STVN), Bausch + Lomb (BLCO), Liquidia (LQDA), LivaNova (LIVN), and Envista (NVST). These companies are all part of the "medical equipment" industry.

How does PROCEPT BioRobotics compare to Stevanato Group?

PROCEPT BioRobotics (NASDAQ:PRCT) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

PROCEPT BioRobotics presently has a consensus target price of $41.45, suggesting a potential upside of 48.96%. Given PROCEPT BioRobotics' higher probable upside, equities analysts plainly believe PROCEPT BioRobotics is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Stevanato Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	5.14	-$95.57M	-$1.82	N/A
Stevanato Group	€1.34B	4.19	€158.21M	€0.59	31.49

In the previous week, Stevanato Group had 2 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 5 mentions for Stevanato Group and 3 mentions for PROCEPT BioRobotics. Stevanato Group's average media sentiment score of 0.67 beat PROCEPT BioRobotics' score of 0.00 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Stevanato Group has a net margin of 11.76% compared to PROCEPT BioRobotics' net margin of -31.82%. Stevanato Group's return on equity of 10.27% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Stevanato Group	11.76%	10.27%	6.08%

PROCEPT BioRobotics has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.78, suggesting that its share price is 22% less volatile than the broader market.

Summary

Stevanato Group beats PROCEPT BioRobotics on 11 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Bausch + Lomb had 2 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 5 mentions for Bausch + Lomb and 3 mentions for PROCEPT BioRobotics. Bausch + Lomb's average media sentiment score of 0.72 beat PROCEPT BioRobotics' score of 0.00 indicating that Bausch + Lomb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PROCEPT BioRobotics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PROCEPT BioRobotics has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.08	-$360M	-$0.62	N/A
PROCEPT BioRobotics	$308.05M	5.14	-$95.57M	-$1.82	N/A

Bausch + Lomb currently has a consensus target price of $17.92, indicating a potential upside of 15.73%. PROCEPT BioRobotics has a consensus target price of $41.45, indicating a potential upside of 48.96%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43

Bausch + Lomb has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Bausch + Lomb has a net margin of -4.21% compared to PROCEPT BioRobotics' net margin of -31.82%. Bausch + Lomb's return on equity of 3.60% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

Summary

PROCEPT BioRobotics beats Bausch + Lomb on 9 of the 16 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Liquidia?

PROCEPT BioRobotics (NASDAQ:PRCT) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

PROCEPT BioRobotics has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

In the previous week, Liquidia had 3 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 6 mentions for Liquidia and 3 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 0.00 beat Liquidia's score of -0.15 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Liquidia	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Liquidia has a net margin of 7.74% compared to PROCEPT BioRobotics' net margin of -31.82%. Liquidia's return on equity of 46.82% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
Liquidia	7.74%	46.82%	7.06%

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 64.5% of Liquidia shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 25.6% of Liquidia shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Liquidia has lower revenue, but higher earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05M	5.14	-$95.57M	-$1.82	N/A
Liquidia	$158.32M	34.74	-$68.92M	$0.14	441.79

PROCEPT BioRobotics presently has a consensus target price of $41.45, suggesting a potential upside of 48.96%. Liquidia has a consensus target price of $55.63, suggesting a potential downside of 10.06%. Given PROCEPT BioRobotics' higher probable upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
Liquidia	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.91

Summary

Liquidia beats PROCEPT BioRobotics on 11 of the 17 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to LivaNova?

LivaNova (NASDAQ:LIVN) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

LivaNova has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

LivaNova presently has a consensus target price of $79.38, indicating a potential upside of 9.69%. PROCEPT BioRobotics has a consensus target price of $41.45, indicating a potential upside of 48.96%. Given PROCEPT BioRobotics' higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43

LivaNova has a net margin of 7.48% compared to PROCEPT BioRobotics' net margin of -31.82%. LivaNova's return on equity of 16.48% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	7.48%	16.48%	7.59%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 0.4% of LivaNova shares are owned by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

PROCEPT BioRobotics has lower revenue, but higher earnings than LivaNova. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	2.86	-$242.47M	$1.95	37.11
PROCEPT BioRobotics	$308.05M	5.14	-$95.57M	-$1.82	N/A

In the previous week, LivaNova and LivaNova both had 3 articles in the media. LivaNova's average media sentiment score of 0.09 beat PROCEPT BioRobotics' score of 0.00 indicating that LivaNova is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PROCEPT BioRobotics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LivaNova beats PROCEPT BioRobotics on 10 of the 15 factors compared between the two stocks.

How does PROCEPT BioRobotics compare to Envista?

Envista (NYSE:NVST) and PROCEPT BioRobotics (NASDAQ:PRCT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, PROCEPT BioRobotics had 3 more articles in the media than Envista. MarketBeat recorded 3 mentions for PROCEPT BioRobotics and 0 mentions for Envista. Envista's average media sentiment score of 0.50 beat PROCEPT BioRobotics' score of 0.00 indicating that Envista is being referred to more favorably in the media.

Company	Overall Sentiment
Envista	Positive
PROCEPT BioRobotics	Neutral

Envista has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.38	$47M	$0.41	56.29
PROCEPT BioRobotics	$308.05M	5.14	-$95.57M	-$1.82	N/A

Envista has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, PROCEPT BioRobotics has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. 1.0% of Envista shares are owned by company insiders. Comparatively, 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Envista presently has a consensus target price of $28.83, suggesting a potential upside of 24.94%. PROCEPT BioRobotics has a consensus target price of $41.45, suggesting a potential upside of 48.96%. Given PROCEPT BioRobotics' stronger consensus rating and higher possible upside, analysts plainly believe PROCEPT BioRobotics is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43

Envista has a net margin of 2.41% compared to PROCEPT BioRobotics' net margin of -31.82%. Envista's return on equity of 7.11% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%

Summary

Envista beats PROCEPT BioRobotics on 9 of the 16 factors compared between the two stocks.

Get PROCEPT BioRobotics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRCT vs. The Competition

Export

Metric	PROCEPT BioRobotics	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.58B	$7.25B	$6.68B	$11.99B
Dividend Yield	N/A	1.20%	2.67%	5.55%
P/E Ratio	-15.29	45.87	24.06	23.63
Price / Sales	5.14	73.75	516.18	112.45
Price / Cash	N/A	24.67	42.23	54.60
Price / Book	4.25	6.95	9.73	6.35
Net Income	-$95.57M	$159.22M	$3.57B	$337.59M
7 Day Performance	5.70%	-2.59%	-1.28%	-2.52%
1 Month Performance	9.39%	1.84%	1.38%	-0.03%
1 Year Performance	-55.76%	-1.02%	23.93%	25.34%

PROCEPT BioRobotics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRCT PROCEPT BioRobotics	2.6928 of 5 stars	$27.83 +3.1%	$41.45 +49.0%	-55.8%	$1.58B	$308.05M	N/A	430
STVN Stevanato Group	2.3485 of 5 stars	€18.86 -0.1%	N/A	-21.9%	€5.71B	€1.34B	31.97	6,010	Analyst Forecast
BLCO Bausch + Lomb	4.1321 of 5 stars	$15.37 -1.8%	$18.08 +17.7%	+32.4%	$5.58B	$5.10B	N/A	13,000	Analyst Forecast
LQDA Liquidia	2.2763 of 5 stars	$58.74 -5.0%	$50.88 -13.4%	+241.0%	$5.50B	$288.07M	419.60	50	Analyst Forecast Insider Trade
LIVN LivaNova	2.7091 of 5 stars	$73.81 +0.0%	$79.38 +7.5%	+57.5%	$4.05B	$1.43B	37.85	3,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRCT) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PROCEPT BioRobotics (PRCT) Competitors

PRCT vs. STVN, BLCO, LQDA, LIVN, and NVST

How does PROCEPT BioRobotics compare to Stevanato Group?

Summary

How does PROCEPT BioRobotics compare to Bausch + Lomb?

Summary

How does PROCEPT BioRobotics compare to Liquidia?

Summary

How does PROCEPT BioRobotics compare to LivaNova?

Summary

How does PROCEPT BioRobotics compare to Envista?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRCT vs. The Competition

PROCEPT BioRobotics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PROCEPT BioRobotics (PRCT) Competitors

PRCT vs. STVN, BLCO, LQDA, LIVN, and NVST

How does PROCEPT BioRobotics compare to Stevanato Group?

Do analysts prefer PRCT or STVN?

Which has better earnings & valuation, PRCT or STVN?

Does the media refer more to PRCT or STVN?

Do institutionals and insiders have more ownership in PRCT or STVN?

Is PRCT or STVN more profitable?

Which has more risk & volatility, PRCT or STVN?

Summary

How does PROCEPT BioRobotics compare to Bausch + Lomb?

Do insiders & institutionals hold more shares of BLCO or PRCT?

Does the media refer more to BLCO or PRCT?

Which has better valuation & earnings, BLCO or PRCT?

Do analysts recommend BLCO or PRCT?

Which has more risk & volatility, BLCO or PRCT?

Is BLCO or PRCT more profitable?

Summary

How does PROCEPT BioRobotics compare to Liquidia?

Which has more risk & volatility, PRCT or LQDA?

Does the media refer more to PRCT or LQDA?

Is PRCT or LQDA more profitable?

Do insiders and institutionals hold more shares of PRCT or LQDA?

Which has better earnings & valuation, PRCT or LQDA?

Do analysts rate PRCT or LQDA?

Summary

How does PROCEPT BioRobotics compare to LivaNova?

Which has more volatility & risk, LIVN or PRCT?

Do analysts rate LIVN or PRCT?

Is LIVN or PRCT more profitable?

Do institutionals & insiders believe in LIVN or PRCT?

Which has stronger valuation & earnings, LIVN or PRCT?

Does the media prefer LIVN or PRCT?

Summary

How does PROCEPT BioRobotics compare to Envista?

Does the media prefer NVST or PRCT?

Which has better valuation and earnings, NVST or PRCT?

Which has more volatility & risk, NVST or PRCT?

Do insiders and institutionals have more ownership in NVST or PRCT?

Do analysts prefer NVST or PRCT?

Is NVST or PRCT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRCT vs. The Competition

PROCEPT BioRobotics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools